Cargando…

649. Prospective Validation of an 11-mRNA Host Immune Signature as a Novel Blood Test for Acute Septic Arthritis

BACKGROUND: Septic arthritis is an orthopedic emergency requiring immediate surgical intervention. Joint aspirations detect inflammatory cells within hours but often cannot distinguish between infections (e.g., bacterial) or other causes (e.g., gout). Cultures take days, so decisions about surgery a...

Descripción completa

Detalles Bibliográficos
Autores principales: Schultz, Blake, Sweeney, Timothy E, Remmel, Melissa, Midic, Uros, Liesenfeld, Oliver, DeBaun, Malcolm, Gardner, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811011/
http://dx.doi.org/10.1093/ofid/ofz360.717
_version_ 1783462375265927168
author Schultz, Blake
Sweeney, Timothy E
Remmel, Melissa
Midic, Uros
Liesenfeld, Oliver
DeBaun, Malcolm
Gardner, Michael
author_facet Schultz, Blake
Sweeney, Timothy E
Remmel, Melissa
Midic, Uros
Liesenfeld, Oliver
DeBaun, Malcolm
Gardner, Michael
author_sort Schultz, Blake
collection PubMed
description BACKGROUND: Septic arthritis is an orthopedic emergency requiring immediate surgical intervention. Joint aspirations detect inflammatory cells within hours but often cannot distinguish between infections (e.g., bacterial) or other causes (e.g., gout). Cultures take days, so decisions about surgery are made with incomplete data. Aspirations carry risk and require technical skill and advanced imaging. Novel diagnostics are thus needed. An 11-mRNA host immune blood signature has been validated to distinguish between infectious and noninfectious acute inflammation. It is part of the 29-mRNA HostDx™ Sepsis test that can also distinguish between bacterial and viral infections and predicts severity (currently under development as a rapid point-of-care test). We studied whether the 11-mRNA signature can determine if acute arthritis was due to an infectious cause. METHODS: We conducted a blinded, prospective, noninterventional study on patients undergoing workup for a septic primary joint. Patients received standard-of-care including joint aspiration and lab tests: White Blood Cells (WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and joint fluid analysis. Simultaneously, blood was drawn (PAXgene RNA tubes). mRNAs were measured on NanoString nCounter™ blinded to clinical results. RESULTS: 20 patients were included, of which 10 had infections based on positive synovial fluid cultures. The 11-mRNA blood signature had an area under the ROC curve (AUROC) of 0.87 for separating infectious from noninfectious conditions compared with 0.58 (ESR), 0.60 (CRP), and 0.50 (WBC); AUROC for synovial WBC was 0.54. At 100% sensitivity for infection, specificity of the signature was 40%; thus, a substantial fraction of nonseptic patients could have been ruled out for further surgical intervention. CONCLUSION: The 11-mRNA signature showed markedly increased accuracy in predicting septic joints compared with routine diagnostic markers. As a quick point-of-care test this blood RNA signature may be an important tool for early, accurate identification of acute septic joints and need for emergent surgery, thereby improving clinical care and healthcare spending. These findings further add to the generalizability of results obtained in the HostDx Sepsis test. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6811011
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68110112019-10-28 649. Prospective Validation of an 11-mRNA Host Immune Signature as a Novel Blood Test for Acute Septic Arthritis Schultz, Blake Sweeney, Timothy E Remmel, Melissa Midic, Uros Liesenfeld, Oliver DeBaun, Malcolm Gardner, Michael Open Forum Infect Dis Abstracts BACKGROUND: Septic arthritis is an orthopedic emergency requiring immediate surgical intervention. Joint aspirations detect inflammatory cells within hours but often cannot distinguish between infections (e.g., bacterial) or other causes (e.g., gout). Cultures take days, so decisions about surgery are made with incomplete data. Aspirations carry risk and require technical skill and advanced imaging. Novel diagnostics are thus needed. An 11-mRNA host immune blood signature has been validated to distinguish between infectious and noninfectious acute inflammation. It is part of the 29-mRNA HostDx™ Sepsis test that can also distinguish between bacterial and viral infections and predicts severity (currently under development as a rapid point-of-care test). We studied whether the 11-mRNA signature can determine if acute arthritis was due to an infectious cause. METHODS: We conducted a blinded, prospective, noninterventional study on patients undergoing workup for a septic primary joint. Patients received standard-of-care including joint aspiration and lab tests: White Blood Cells (WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and joint fluid analysis. Simultaneously, blood was drawn (PAXgene RNA tubes). mRNAs were measured on NanoString nCounter™ blinded to clinical results. RESULTS: 20 patients were included, of which 10 had infections based on positive synovial fluid cultures. The 11-mRNA blood signature had an area under the ROC curve (AUROC) of 0.87 for separating infectious from noninfectious conditions compared with 0.58 (ESR), 0.60 (CRP), and 0.50 (WBC); AUROC for synovial WBC was 0.54. At 100% sensitivity for infection, specificity of the signature was 40%; thus, a substantial fraction of nonseptic patients could have been ruled out for further surgical intervention. CONCLUSION: The 11-mRNA signature showed markedly increased accuracy in predicting septic joints compared with routine diagnostic markers. As a quick point-of-care test this blood RNA signature may be an important tool for early, accurate identification of acute septic joints and need for emergent surgery, thereby improving clinical care and healthcare spending. These findings further add to the generalizability of results obtained in the HostDx Sepsis test. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6811011/ http://dx.doi.org/10.1093/ofid/ofz360.717 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Schultz, Blake
Sweeney, Timothy E
Remmel, Melissa
Midic, Uros
Liesenfeld, Oliver
DeBaun, Malcolm
Gardner, Michael
649. Prospective Validation of an 11-mRNA Host Immune Signature as a Novel Blood Test for Acute Septic Arthritis
title 649. Prospective Validation of an 11-mRNA Host Immune Signature as a Novel Blood Test for Acute Septic Arthritis
title_full 649. Prospective Validation of an 11-mRNA Host Immune Signature as a Novel Blood Test for Acute Septic Arthritis
title_fullStr 649. Prospective Validation of an 11-mRNA Host Immune Signature as a Novel Blood Test for Acute Septic Arthritis
title_full_unstemmed 649. Prospective Validation of an 11-mRNA Host Immune Signature as a Novel Blood Test for Acute Septic Arthritis
title_short 649. Prospective Validation of an 11-mRNA Host Immune Signature as a Novel Blood Test for Acute Septic Arthritis
title_sort 649. prospective validation of an 11-mrna host immune signature as a novel blood test for acute septic arthritis
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811011/
http://dx.doi.org/10.1093/ofid/ofz360.717
work_keys_str_mv AT schultzblake 649prospectivevalidationofan11mrnahostimmunesignatureasanovelbloodtestforacutesepticarthritis
AT sweeneytimothye 649prospectivevalidationofan11mrnahostimmunesignatureasanovelbloodtestforacutesepticarthritis
AT remmelmelissa 649prospectivevalidationofan11mrnahostimmunesignatureasanovelbloodtestforacutesepticarthritis
AT midicuros 649prospectivevalidationofan11mrnahostimmunesignatureasanovelbloodtestforacutesepticarthritis
AT liesenfeldoliver 649prospectivevalidationofan11mrnahostimmunesignatureasanovelbloodtestforacutesepticarthritis
AT debaunmalcolm 649prospectivevalidationofan11mrnahostimmunesignatureasanovelbloodtestforacutesepticarthritis
AT gardnermichael 649prospectivevalidationofan11mrnahostimmunesignatureasanovelbloodtestforacutesepticarthritis